Clinical

Dataset Information

0

Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer


ABSTRACT: This is a randomized phase III study with a safety lead-in part in patients with KRAS/ NRAS and BRAF Wild Type metastatic colorectal cancer who have previously received treatment with oxaliplatin, irinotecan, fluoropyrimidines, anti-VEGF agents and anti-EGFR antibodies. The main objective of the safety lead-in part is to assess safety and tolerability of futuximab/modotuximab in combination with trifluridine/tipiracil. The primary objective of the phase III part is to compare Overall Survival of futuximab/modotuximab in combination with trifluridine/tipiracil vs trifluridine/tipiracil monotherapy in patients with tumours that are KRAS/NRAS and BRAF wild-type (WT) (Double negative [DN].

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Cancer,Colorectal Cancer Metastatic,Colorectal Neoplasms

PROVIDER: 2403437 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2386782 | ecrin-mdr-crc
| 2366035 | ecrin-mdr-crc
| 2352790 | ecrin-mdr-crc
| 60837 | ecrin-mdr-crc
| S-EPMC8658167 | biostudies-literature
2017-09-25 | GSE96786 | GEO
2017-09-25 | GSE96785 | GEO
| 2307445 | ecrin-mdr-crc
| 2383608 | ecrin-mdr-crc
| 2401722 | ecrin-mdr-crc